Evidence map›Paper›PMID 40590391›Full record

ReviewVirulence2025

The relationship between HERVs and exogenous viral infections: A focus on the value of HERVs in disease prediction and treatment.

Anhua Dou, Juan Xu, Chenglin Zhou

Abstract readReview
In one paragraph

Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anhua DouClinical Medical Laboratory Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.ORCID 0009-0000-9916-3915
Juan XuClinical Medical Laboratory Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Chenglin ZhouClinical Medical Laboratory Center, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.ORCID 0000-0003-2661-2067

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human endogenous retroviruses (HERVs) are virus-related sequences that are a normal part of the human genome; they account for about 8% of the human genome. Reactivation of these ancestral proviral sequences can lead to the generation of functional products. Several reactivated HERVs are associated with cancer and autoimmune diseases. Emerging research suggests that reactivated HERVs may play a significant role in the development of viral diseases such as acquired immune deficiency syndrome (AIDS) and coronavirus disease 2019 (COVID-19), as well as in neuroinflammatory diseases possibly triggered by viral factors, such as multiple sclerosis (MS). Studies exploring the relationship between HERVs and exogenous viral infections have the potential to offer a fresh perspective on developing treatment and prevention strategies for exogenous viral infections. The mechanism of the transactivation of HERVs caused by exogenous viral infection, as well as the contribution of HERVs to viral diseases or diseases triggered by viral factors, deserve further research. Here, we review the relationship between exogenous viruses and HERVs in several common diseases caused or triggered by viral infections, with a focus on the value of HERVs as biomarkers for forecasting disease advancement or prognosis and as potential targets for therapeutic interventions.

Indexed as

Endogenous RetrovirusesVirus DiseasesBiomarkersCOVID-19HumansMultiple SclerosisSARS-CoV-2BiomarkersCOVID-19epigenetic mechanismHIVHuman endogenous retroviruses(HERVs)multiple sclerosis(MS)transcription

Identifiers

PMID40590391
PMCPMC12218431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.